30
Participants
Start Date
February 28, 2010
Primary Completion Date
January 31, 2015
Study Completion Date
February 29, 2016
BB3
intravenous drug
State University of New York at Buffalo, Buffalo
Medstar Georgetown University Hospital, Washington D.C.
MedStar Washington Hospital Center, Washington D.C.
Division of Transplant Surgery, University of Maryland School of Medicine, University of Maryland Medical Center, Baltimore
The Methodist Hospital, Houston
California Institute of Renal Research, San Diego
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Angion Biomedica Corp
INDUSTRY